Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Study shows CEL-2000 vaccine blocks RA progression in mice

CEL-SCI Corporation and their scientific collaborators announced today that the Company's CEL-2000 vaccine demonstrated that it is able to block the progression of rheumatoid arthritis (RA) in a mouse model.

23 Feb 2010

Amgen's Prolia Complete Response submission: FDA classifies and sets PDUFA date

Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has evaluated the content of the Company's Complete Response submission for Prolia™ (denosumab) in the treatment of postmenopausal osteoporosis and classified it as a Class 2 resubmission. With the Class 2 designation, the FDA set a corresponding Prescription Drug User Fee Act (PDUFA) action date of July 25, 2010.

20 Feb 2010

Contrast-enhanced MRI may help physicians differentiate between rheumatoid and psoriatic arthritis

Contrast-enhanced magnetic resonance imaging (MRI) may help physicians differentiate between rheumatoid arthritis and psoriatic arthritis in the hand and wrist enabling more targeted therapies unique to each condition, according to a study in the March issue of the American Journal of Roentgenology. Contrast-enhanced MRI uses contrast media to improve the visibility of internal bodily structures.

19 Feb 2010

FDA approves Rituxan-FC combination therapy for CLL

Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec announced today the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab) in combination with fludarabine and cyclophosphamide (FC) for people with previously untreated and previously treated CD20-positive chronic lymphocytic leukemia (CLL).

18 Feb 2010

Incyte announces 2009 financial results and key fourth-quarter accomplishments

Incyte Corporation today reported fourth quarter and full year 2009 financial results, provided an update on key fourth quarter accomplishments and 2010 objectives, and announced its 2010 financial guidance.

18 Feb 2010

Phase 2 study results: VEGF Trap-Eye improves vision in patients with DME

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare AG announced that VEGF Trap-Eye showed positive results in a Phase 2 study in patients with diabetic macular edema (DME).

18 Feb 2010

Signaling protein has key role in fighting bacterial infection and inflammation in intestinal tract: Study

A signaling protein that is key in orchestrating the body's overall immune response has an important localized role in fighting bacterial infection and inflammation in the intestinal tract, according to a study by UC San Diego School of Medicine investigators, published in the journal Cell Host and Microbe.

18 Feb 2010

Biogen Idec, Swedish Orphan Biovitrum restructure collaboration agreement for rFVIIIFc and rFIXFc programs

Biogen Idec and Swedish Orphan Biovitrum today announced that they have restructured the collaboration agreement for the companies’ long-acting, recombinant Factor VIII Fc fusion protein (rFVIIIFc) in hemophilia A patients and the recombinant Factor IX Fc fusion protein (rFIXFc) in hemophilia B patients.

18 Feb 2010

CalciMedica granted U.S. composition patent concerning key component of CRAC channel

CalciMedica today announced that the US Patent and Trademark Office has issued to CalciMedica US Patent No. 7,645,588, a composition patent involving STIM1, a key component of the calcium release-activated calcium (CRAC) channel. The patent, entitled "Composition comprising a cell comprising a STIM1 protein and an agent that modulates intracellular calcium and methods of use," has a priority date of March 4, 2003 and was issued on January 12, 2010.

17 Feb 2010

Combination of daclizumab and interferon beta significantly reduces MS lesion formation

Biogen Idec and Facet Biotech Corporation today announced the publication of Phase 2 data showing that the addition of daclizumab to interferon beta (IFNβ) led to a significant reduction in the number of new or enlarged multiple sclerosis (MS) lesions when compared to IFNβ alone in patients with active relapsing forms of MS.

17 Feb 2010

Amgen and Centocor Ortho Biotech Products: FDA approves REMS for Aranesp, EPOGEN and PROCRIT ESAs

Amgen Inc. and Centocor Ortho Biotech Products, L.P., today announced that the U.S. Food and Drug Administration (FDA) has approved the Risk Evaluation and Mitigation Strategy (REMS) for erythropoiesis-stimulating agents (ESAs), which include Aranesp® (darbepoetin alfa), EPOGEN® (Epoetin alfa) and PROCRIT® (Epoetin alfa).

17 Feb 2010

AstraZeneca, Rigel Pharmaceuticals announce exclusive worldwide license agreement for R788

AstraZeneca and Rigel Pharmaceuticals today announced an exclusive worldwide license agreement for the global development and commercialization of fostamatinib disodium (R788), Rigel's late-stage investigational product for rheumatoid arthritis (RA) and additional indications.

16 Feb 2010

Idera Pharmaceuticals presents TLR antagonist preclinical hyperlipidemia data at Keystone Symposia conference

Idera Pharmaceuticals, Inc. presented data on the evaluation of a Toll-like receptor (TLR) antagonist in a preclinical hyperlipidemia model today at the Keystone Symposia conference “Advances in Molecular Mechanisms of Atherosclerosis” being held in Banff, Alberta, Canada. Idera’s proprietary TLR antagonists have dual activity for both TLR7 and TLR9, and present a potentially innovative approach for the treatment of certain autoimmune diseases.

15 Feb 2010

PAN to provide co-payment assistance for medications to underinsured patients through five new funds

Patient Access Network Foundation will expand its services to provide co-payment assistance for medications to underinsured patients through five new funds -- including grants of up to $10,000 per year for prostate cancer patients.

12 Feb 2010

Antibodies also contribute to severe dengue virus-induced disease, confirms La Jolla Institute for Allergy & Immunology

A leading immunology research institute has validated the long-held and controversial hypothesis that antibodies - usually the "good guys" in the body's fight against viruses - instead contribute to severe dengue virus-induced disease, the La Jolla Institute for Allergy & Immunology announced today. The finding has major implications for the development of a first-ever vaccine against dengue virus, a growing public health threat which annually infects 50 to 100 million people worldwide, causing a half million cases of the severest form.

12 Feb 2010

Routine testing of hs-CRP in women with heart disease is controversial, says Mayo Clinic cardiologist

For women concerned about heart disease, routine testing of high-sensitivity C-reactive protein (hs-CRP) is controversial, says Thomas Behrenbeck, M.D., Ph.D., a Mayo Clinic cardiologist, in an interview in the February issue of Mayo Clinic Women's HealthSource.

12 Feb 2010

Corey McPherson Nash, Biogen Idec team up to create new website for life science community

Corey McPherson Nash (www.corey.com), a leading national branding and design firm, recently partnered with Biogen Idec to create a new Web site design for the life sciences company.

12 Feb 2010

Autism Speaks: Ten most significant autism research achievements in 2009

Autism Speaks, the world's largest autism science and advocacy organization has released its annual list of the 10 most significant research achievements to have impacted autism during the previous year. Every year, Autism Speaks documents the progress made toward its mission to discover the causes and treatment for autism spectrum disorders, and compiles a list of the 10 most significant research achievements to have impacted autism during the previous year.

10 Feb 2010

Ligon Discovery, Lycera announce collaboration to identify drug candidates for immune disorders

Ligon Discovery announced today that it has entered into a collaboration agreement with Lycera Corporation to apply its Small Molecule Microarray (SMM) screening technology to identify first-in-class drug candidates for immune disorders. Ligon will apply its SMM technology to screen protein targets identified by Lycera as critical to the development of certain immune disorders. Financial terms were not disclosed.

10 Feb 2010

Biogen Idec reports 2009 fourth quarter and full year earnings

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2009 results.

9 Feb 2010

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Study shows CEL-2000 vaccine blocks RA progression in mice

Amgen's Prolia Complete Response submission: FDA classifies and sets PDUFA date

Contrast-enhanced MRI may help physicians differentiate between rheumatoid and psoriatic arthritis

FDA approves Rituxan-FC combination therapy for CLL

Incyte announces 2009 financial results and key fourth-quarter accomplishments

Phase 2 study results: VEGF Trap-Eye improves vision in patients with DME

Signaling protein has key role in fighting bacterial infection and inflammation in intestinal tract: Study

Biogen Idec, Swedish Orphan Biovitrum restructure collaboration agreement for rFVIIIFc and rFIXFc programs

CalciMedica granted U.S. composition patent concerning key component of CRAC channel

Combination of daclizumab and interferon beta significantly reduces MS lesion formation

Amgen and Centocor Ortho Biotech Products: FDA approves REMS for Aranesp, EPOGEN and PROCRIT ESAs

AstraZeneca, Rigel Pharmaceuticals announce exclusive worldwide license agreement for R788

Idera Pharmaceuticals presents TLR antagonist preclinical hyperlipidemia data at Keystone Symposia conference

PAN to provide co-payment assistance for medications to underinsured patients through five new funds

Antibodies also contribute to severe dengue virus-induced disease, confirms La Jolla Institute for Allergy & Immunology

Routine testing of hs-CRP in women with heart disease is controversial, says Mayo Clinic cardiologist

Corey McPherson Nash, Biogen Idec team up to create new website for life science community

Autism Speaks: Ten most significant autism research achievements in 2009

Ligon Discovery, Lycera announce collaboration to identify drug candidates for immune disorders

Biogen Idec reports 2009 fourth quarter and full year earnings

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Newsletters you may be interested in